Philogen SpA's revenue for the
six
months ended in Dec. 2025 was €308.8 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2025 was €314.3 Mil.
Philogen SpA's Revenue per Share for the
six
months ended in Dec. 2025 was €7.63.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €7.77.
During the past 12 months, the average Revenue per Share Growth Rate of Philogen SpA was 325.10% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 137.30% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 139.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 6 years, Philogen SpA's highest 3-Year average Revenue per Share Growth Rate was 207.70% per year. The lowest was 63.70% per year. And the median was 137.30% per year.
Philogen SpA (MIL:PHIL) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Philogen SpA Revenue Related Terms
Philogen SpA Revenue Historical Data
* Premium members only.
The historical data trend for Philogen SpA's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Philogen SpA's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Philogen SpA Revenue vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Philogen SpA's Revenue distribution charts can be found below:
* The bar in red indicates where Philogen SpA's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €314.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Philogen SpA (MIL:PHIL) has a Revenue of €314.3 Mil as of Dec. 2025. Revenue is the total amount a company generates as sales through its operations. View historical data on Philogen SpA and its competitors.
Is Philogen SpA's Revenue too high?
Philogen SpA's current Revenue is €314.3 Mil. Overall, Philogen SpA has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Philogen SpA's Revenue compare to VRTX and REGN?
Philogen SpA's Revenue of €314.3 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Philogen SpA and its competitors. Philogen SpA's current Revenue is €314.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Philogen SpA stock overvalued right now?
Based on GuruFocus' analysis, Philogen SpA (MIL:PHIL) is currently considered Possible Value Trap. The stock's GF Value™ is €228.92, compared to a current price of €25.55 — trading 88.8% below its estimated fair value. The current Revenue is €314.3 Mil. Philogen SpA's overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Philogen SpA (MIL:PHIL), the current Revenue is €314.3 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Philogen SpA (MIL:PHIL) Overvalued in 2026?
Based on GuruFocus' analysis, Philogen SpA stock appears to be undervalued.
The current stock price of €25.55 is trading 88.8% below its estimated GF Value™ of €228.92.
GuruFocus considers Philogen SpA to be Possible Value Trap.
Key valuation signals for MIL:PHIL:
Revenue: €314.3 Mil
GF Value™: €228.92 vs. price of €25.55 (88.8% below fair value)
No single metric tells the full story. See the MIL:PHIL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Philogen SpA is a biotechnology company engaged in the research and development of antibody-based therapeutics for the treatment of cancer and chronic inflammatory diseases. The company's pipeline includes products such as Nidlegy, Fibromun, Darleukin, and Dekavil, targeting oncology and other serious conditions. Geographically, the company operates in the European Union, Switzerland, and the United States of America.
61GF Score
Get the complete analysis for MIL:PHIL
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:PHIL has been successfully added to your 
